Across TCGA pan-cancer cohorts, CYRIA Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CYRIA data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher CYRIA Mutation is associated with better overall survival. In most high-consensus cancer types, elevated CYRIA expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

BLCA, PRAD, and LUAD are the cancer types where CYRIA Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	II,III,IV	1.000	0.413	.035	8	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	OS	Median	II,III,IV	0.237	0.709	.039	3	view →
SKCM	DFS	Median	III,IV	0.177	0.659	.010	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: CYRIA tumor-vs-normal RNA expression · all CYRIA data types